Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
367
datasets available to search
ShareScore release 0.9.0
Dataset results
367 results for “Ibrutinib”
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT02251548. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT02801578. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non
ClinicalTrials.gov study NCT01855750. IPD Sharing: Not stated. Countries: 27. Publications: 4.
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
ClinicalTrials.gov study NCT03267186. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated
ClinicalTrials.gov study NCT01974440. IPD Sharing: Not stated. Countries: 19. Publications: 1.
Supplementary data for: Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients
<p>In a clinical trial to evaluate a NEDD8-activating enzyme inhibitor in treating a mantle cell lymphoma patient, peripheral blood mononuclear cells (PBMCs) were collected from the patient at baseline and after 3 and 24 hours after drug infusion. Then, single-cell RNA-seq was conducted on the collected PBMCs. The pre-processed data was saved as a Seurat object.</p>
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
ClinicalTrials.gov study NCT03876028. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression
ClinicalTrials.gov study NCT02863718. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
ClinicalTrials.gov study NCT03425591. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
ClinicalTrials.gov study NCT03770416. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
ClinicalTrials.gov study NCT02419560. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
ClinicalTrials.gov study NCT03703167. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT02007044. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
ClinicalTrials.gov study NCT01880567. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
ClinicalTrials.gov study NCT03980002. IPD Sharing: NO. Countries: 1. Publications: 1.
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
ClinicalTrials.gov study NCT05782374. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
ClinicalTrials.gov study NCT05106296. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
ClinicalTrials.gov study NCT02542514. IPD Sharing: NO. Countries: 1. Publications: 1.
Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leuk
ClinicalTrials.gov study NCT02640209. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT04754035. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.